PTPN11 and Netherton syndrome: Gain-of-function mutations of Shp2 that disrupt the auto-inhibition were reported in Noonan Syndrome (NS), LEOPARD syndrome (LS) and juvenile myelomonocytic leukemia, but Shp2 mutations occur at low frequency in solid tumors7.